The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its first full week after launch, surpassing other GLP-1 starts. Investors eye its edge over Eli Lilly in the competitive obesity market. Oral treatments offer needle-free flexibility for patients.
New research challenges fears of quick weight regain after stopping GLP-1 drugs like Ozempic and Wegovy. Real-world data reveals many patients sustain their losses. Experts say durability is possible without lifelong treatment.
Emilly Murray transformed from 22st 2lbs to a slim 9st using Mounjaro, conquering binge eating and food noise. After hitting a plateau at 11st, she boosted water intake to 2-3 liters daily and increased meat and fish consumption. This simple strategy reignited her weight loss toward her 10st goal.
Sun Pharmaceutical Industries secures approval to manufacture and sell generic Wegovy in India. The generic semaglutide, branded Noveltreat, launches after March 2026 patent expiry. Indian firms race to tap the booming GLP-1 weight loss market.
Radio host Matt Cooper reveals his journey as an early Ozempic adopter for type 2 diabetes. He defends users struggling with weight, sharing how the GLP-1 drug curbs appetite and led to gallbladder removal. Learn from his candid experiences on semaglutide benefits and challenges.
A scientific review shows certain affordable foods and drinks, including a 4p cup of green tea, could mimic GLP-1 inhibitors used in weight loss drugs. These natural compounds may support appetite regulation and blood sugar control. However, experts caution they are not direct alternatives to medications like Ozempic.
Stars using GLP-1 medications like Ozempic for dramatic weight loss are sparking talk of 'Ozempic face': sunken cheeks, new wrinkles, and sagging skin. Cleveland Clinic endocrinologist Vinni Makin notes this gaunt look stems from rapid fat loss. Public figures face scrutiny as the trend grows.
Corxel Pharmaceuticals raises $287 million in Series D funding to fuel phase 2/3 studies of its oral GLP-1 receptor agonist CX11 for obesity. Early phase 2 data shows a 9.7% body weight reduction at 16 weeks with high-dose titration. The funding also supports global trials and other cardiometabolic assets.
A new University of Oxford study reveals that GLP-1 users regain weight rapidly after stopping medications like Ozempic, with cardiometabolic benefits reversing within two years. This underscores the need for portion-controlled, nutrient-dense foods to maintain satiety on fewer calories. Food innovation will play a key role in supporting former users.
